奥布替尼联合R-CHOP方案治疗新诊断高危伴结外累及non-GCB弥漫大B细胞淋巴瘤的临床研究
回顾性纳入35例经免疫组化证实、国际预后指数3~5分且PET-CT证实≥2处结外受累的高危non-GCB弥漫大B细胞淋巴瘤患者,接受标准R-CHOP联合奥布替尼150 mg/d共6个周期。ORR 88.6%,CR率68.6%,2年PFS率68.6%、OS率87.5%;双表达患者2年PFS率低于非双表达患者(P=0.048)。严重不良事件包括发热性中性粒细胞减少症、肺炎和心房扑动,无治疗相关死亡。
要点
- 35例高危伴结外累及non-GCB DLBCL接受奥布替尼联合R-CHOP,ORR 88.6%、CR率68.6%。
- 2年PFS率68.6%、2年OS率87.5%,中位随访28个月。
- 双表达患者2年PFS率54.4%低于非双表达85.2%(P=0.048)。
核心结论
- 在高危伴结外受累的non-GCB DLBCL患者中,奥布替尼联合R-CHOP方案治疗显示出较好的疗效和可控的不良反应。
研究设计与样本
- 回顾性研究,纳入2021年1月至2022年12月广西医科大学附属肿瘤医院淋巴血液肿瘤科收治的DLBCL患者35例。
- 入组条件为经免疫组化证实non-GCB DLBCL、国际预后指数评分3~5分、PET-CT证实≥2处结外受累。
- 治疗方案为标准R-CHOP方案联合奥布替尼口服150 mg/d,完成6个周期。
- 治疗中出现中性粒细胞缺乏症或3级中性粒细胞减少伴发热者,下一周期开始在化疗结束48 h后给予预防性聚乙二醇化粒细胞集落刺激因子。
主要发现
- 患者中位年龄53(21~72)岁,中位随访时间28(12~36)个月,其中19例为双表达患者。
- ORR为88.6%,CR率为68.6%。
- 2年PFS率为68.6%(95% CI 54.0%~87.2%),2年OS率为87.5%(95% CI 76.7%~100%)。
- 双表达患者2年PFS率54.4%(95% CI 35.4%~84.2%)低于非双表达患者85.2%(95% CI 68.3%~100%),P=0.048。
- 严重不良事件包括发热性中性粒细胞减少症、肺炎和心房扑动,未观察到治疗相关死亡病例。
临床怎么用
- 原文结论认为,在高危伴结外受累的non-GCB DLBCL患者中,奥布替尼联合R-CHOP方案治疗显示出较好的疗效和可控的不良反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the efficacy and safety of orelabrutinib combined with R-CHOP in patients with high-risk nongerminal center B-cell (non-GCB) diffuse large B-cell lymphoma (DLBCL) with extranodal involvement. Methods: This retrospective study was conducted on 35 patients who were seen at Guangxi Medical University Cancer Hospital and were immunohistochemically confirmed to have non-GCB DLBCL, had an International Prognostic Index score of 3 - 5, and confirmed to have ≥2 extranodal involvement on PET/CT. The treatment comprised the standard R-CHOP regimen combined with oral orelabrutinib (150 mg/day) for six cycles. In patients who developed neutropenia or grade 3 neutropenia with fever during treatment, administration of prophylactic pegylated granulocyte colony-stimulating factor 48 h after the end of chemotherapy was started on the next cycle. The endpoints included overall response rate (ORR), complete response (CR) rate, progression-free survival (PFS) time, overall survival (OS) time, and safety assessment. Results: The 35 eligible patients enrolled had a median age of 53 years (21 - 72 years) and a median follow-up time of 28 months (12 - 36 months) ; 19 patients had double-expressor (DE) status. The ORR was 88.6%, and the CR rate was 68.6%. The 2-year PFS and OS rates were 68.6% (95% CI 54.0% - 7.2%) and 87.5% (95% CI 76.7% - 100%), respectively. The 2-year PFS rate was significantly lower in patients with DE status than in those without DE status [54.4% (95% CI 35.4% - 84.2%) vs. 85.2% (95% CI 68.3% - 100%), P=0.048]. Serious adverse events included febrile neutropenia, pneumonia, and atrial flutter, but no treatment-related deaths. Conclusion: In patients with high-risk non-GCB DLBCL and extranodal involvement, the combination of orelabrutinib with R-CHOP regimen had good efficacy and manageable toxicity. 目的: 探索奥布替尼与R-CHOP方案联合使用,治疗高危伴结外累及的非生发中心起源的弥漫大B细胞淋巴瘤(non-GCB DLBCL)患者的疗效与安全性。 方法: 回顾性纳入2021年1月至2022年12月期间广西医科大学附属肿瘤医院淋巴血液肿瘤科收治的DLBCL患者35例。患者为经免疫组化证实、国际预后指数评分为3~5分,且经PET-CT证实存在2处或以上结外受累的non-GCB DLBCL。治疗方案为标准R-CHOP方案联合奥布替尼口服(150 mg/d),完成6个周期治疗。对于治疗中出现中性粒细胞缺乏症或3级中性粒细胞减少伴有发热的患者,下一个周期开始在化疗结束48 h后给予预防性聚乙二醇化粒细胞集落刺激因子治疗。观测终点包括有效率(ORR)、完全缓解(CR)率、无进展生存(PFS)期、总生存(OS)期和安全性评估。 结果: 患者中位年龄53(21~72)岁,中位随访时间为28(12~36)个月,其中19例为双表达患者。ORR为88.6%,CR率为68.6%,2年PFS率和OS率分别为68.6%(95% CI 54.0%~87.2%)和87.5%(95% CI 76.7%~100%)。双表达DLBCL患者的2年PFS率低于非双表达患者[54.4%(95% CI 35.4%~84.2%)对85.2%(95% CI 68.3%~100%),P=0.048]。严重不良事件包括发热性中性粒细胞减少症、肺炎和心房扑动,未观察到治疗相关死亡病例。 结论: 在高危伴有结外受累的non-GCB DLBCL患者中,奥布替尼联合R-CHOP方案治疗显示出较好的疗效和可控的不良反应。.
引用
- Guo BP, Wang MY, Liao CC, et al. [Clinical study of orelabrutinib combined with R-CHOP regimen for newly diagnosed high-risk non-GCB diffuse large B-cell lymphoma with extranodal involvement]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40134200. doi:10.3760/cma.j.cn121090-20240914-00347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。